Q-omics provides the consensus-scored KLHDC7A profile across patient tissues and cancer cell-line models. KLHDC7A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KLHDC7A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, KLHDC7A RNA expression shows 13,885 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where KLHDC7A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHDC7A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHDC7A survival associations across molecular data types. KLHDC7A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHDC7A RNA expression–survival associations across cancer types. High KLHDC7A expression shows unfavorable associations in LGG, but favorable associations in KIRC, KIRP, BLCA, STAD and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KLHDC7A RNA expression.
This table summarizes KLHDC7A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KLHDC7A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHDC7A shows lower tumor expression in HNSC, KICH, KIRC, COAD and LUSC and higher tumor expression in UCEC. The HNSC box plot shows higher KLHDC7A RNA expression in normal versus tumor tissue (log2 FC = −1.355, t-test p < 0.001).
This table shows molecular features associated with KLHDC7A in patient tissues and cancer cell lines. In patient samples, KLHDC7A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHDC7A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
